Gyala Therapeutics

Gyala Therapeutics is a spin-off company founded by Hospital Clínic de Barcelona – IDIBAPS. The company is focused on developing CAR-T therapies against a novel target for hematological malignancies, such as acute myeloid leukaemia. The company leverages the experience gathered at Hospital Clínic de Barcelona in the development and authorization of CAR-T ARI-0001 against CD19.